Articles On Antisense Therapeutics (ASX:ANP)

ShareCafeAus shares close 0.3% lower on inflation data by Peter Milios   The Australian Treasurer, Jim Chalmers, held a press conference addressing the “unacceptably high” inflation figures released today. He acknowledged the high figures,...

ShareCafeASX down 0.3% at noon after new inflation data by Peter Milios   Australian inflation has grown at a rate of 7.8 per cent in the December quarter, which is higher than expected. This has reinforced the case for the Reserve Bank to...

It can take a long time to bring a new drug to market, but companies that succeed reap mighty rewards. Any time a company is working in drug manufacturing and clinical research, the compound needs to be tested on human subjects to ensure...

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

ShareCafeASX falls after lithium stocks crumble: ASX closes 0.07% lower by Peter Milios   Sectors were mostly mixed today, and the S&P/ASX 200 was 0.07 per cent or 4.70 points lower at 7141.6 at the closing bell. Healthcare slightly edg...

ShareCafeSlow start to week continues as RBA hints further hikes: ASX down 0.35% at noon by Lauren Hayes   Following a choppy US session overnight, the Australian market is marginally lower this morning. Materials have erased some of yester...

Antisense Therapeutics (ANP) announces the retirement of its CEO and Managing Director, Mark Diamond, after 21 years in the positionHe will continue his responsibilities as CEO until a successor is appointed, with the board to begin its sea...

ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios   All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi...

Antisense Therapeutics (ANP) is set to conduct a nine-month chronic monkey toxicology study in the US to progress its Duchenne muscular dystrophy drug, ATL1102The study is the final step required for lifting ANP’s partial clinical hold that...

ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes   Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise...

EMV Medical Devices delivered its first portable brain scanner Firebrick Pharma gets patent in Australia Antisense to progress on clinical trial EMVision delivers first brain scanner EMVision Medical Devices (ASX:EMV) jumped 7% after anno...

ASX health stocks extend weekly gains on Friday as markets rally on back of promising US inflation figures Wound care company Avita rises 24% and biotech Antisense is up 18% for past five days Fertility company Monash IVF provides solid H1...

ShareCafeAntisense (ASX: ANP) Discuss Upcoming AGM & New Appointment Antisense Therapeutics Limited (ASX: ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense’s progress, attracti...

ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios   CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Antisense Therapeutics (ASX:ANP) has commenced dosing in a muscular dystrophy mouse model of Duchenne muscular dystrophy to assess the potential clinical utility of ATL1102 in combination with dystrophin restoration drugs.

Antisense Therapeutics (ANP) kicks off a mouse study to test the clinical utility of its ATL1102 product in combination with other drugs to treat Duchenne Muscular DystrophyAs part of the study, Antisense will dose mice with an antisense ol...

ShareCafeAntisense Therapeutics (ASX:ANP) – Revised Clinical Plans Presentation Antisense Therapeutics Limited (ASX:ANP) CEO and Managing Director Mark Diamond and Chair Charmaine Gittleson discuss the company’s revised clinical developmen...

Antisense Therapeutics Limited (ASX:ANP) has announced that it intends to conduct a double-blind, placebo-controlled six-month dosing trial of ATL1102 followed by a six-month open-label phase 2b trial in non-ambulant boys with Duche...

ShareCafeEvening Report: 7 September, 2022 by Paul Sanger   Australian shares touched a near seven-week low, a day after the country’s central bank raised rates, as a slide in commodity stocks and Wall Street weighed on the benchmark index....

Highlights: The ASX 200 benchmark index closed 1.42% down at 6,729.30 points today. Over the last five days, the index has lost 3.69% and 10.64% over the last 52 weeks. IT was the best performing sector today, gaining 0.33%, while ene...

Antisense Therapeutics (ANP) revises the design of a planned clinical trial for its ATL1102 product to bring forward its data reporting capabilities and cut costsThe company had initially planned for the trial’s Data Safety Monitoring Board...

ShareCafeLunch Report: 7 September, 2022 by Paul Sanger   Australian shares have started the day lower, taking cues from Wall Street as traders assess fresh US economic data in volatile trading. At noon, the S&P/ASX 200 is 1.33 per cent...

ShareCafeStocks of the Hour: 7 September, 2022                    Antisense Therapeutics Limited (ASX:ANP) today announced that it intends to conduct a double-blind, placebo controlled six month dosing trial of ATL1102 followed by a s...

07 Sep 2022 - A snapshot of the stocks on the move featuring Antisense Therapeutics (ASX:ANP), Euro Manganese (ASX:EMN) and Lake Resources (ASX:LKE).

ShareCafeThe Week that Was – August 29-September 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

ShareCafeAntisense Taking a Quick Approach to Long COVID Corporate Connect Analyst Marc Sinatra has released an update on local biotech Antisense Therapeutics (ASX: ANP) in the wake of a collaborative study Antisense undertook involving Lon...

Antisense Therapeutics (ASX:ANP) has announced outcomes from its collaboration to study the neurological aspects of Long COVID-19 with US-based researchers.

Antisense Therapeutics (ANP) announces the outcomes of its collaboration to study the neurological aspects of long COVID-19 in patients who hadn’t been hospitalised Blood samples were collected and used to generate data on up to 7000 prote...

ShareCafeLunch Report: 19 August, 2022 by Paul Sanger   At noon, the S&P/ASX 200 is 0.07 per cent or 5.30 points higher at 7118.10. Coal mining stocks on the move again today. Terracom (ASX:TER) up 6.15 per cent, Whitehaven Coal ( ASX:W...

19 Aug 2022 - A snapshot of the stocks on the move featuring Antisense Therapeutics (ASX:ANP), Thorn Group (ASX:TGA) and Mt Monger Resources (ASX:MTM).

Invex receives IND approval from the US FDA Antisense reveals positive study in Long Covid-19 Bod gets US certification Invex Therapeutics (ASX:IXC) jumped 20% this morning after receiving a Investigational New Drug Application (IND) appr...

The ASX200 is riding Wall Street’s coattails today up 044% Nine out of eleven sectors were higher, with real estate leading the charge Technology was a close second with the help of a unicorn takeover bid   Wall Street rallied on Friday a...

ShareCafeLunch Report: 5 August, 2022 by Tim McGowen   Gold stocks are stronger across the board as the price of gold reaches one month highs as the $US weakens and geopolitical tensions rise with China & Taiwan. The annual Diggers &amp...

Mach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after device submission for FebriDX rejected by US FDA Three companies announce major milestones in clinical trials Healthcare and life sciences e...

Antisense Therapeutics (ANP) submits its first clinical trial application for the Phase 2b/3 clinical trial of its drug aiming to treat muscular dystrophy The application has been submitted to the Federal Institute for Drugs and Medical De...

ShareCafeANP – Morgans rates the stock as Speculative Buy Morgans notes that access to capital within the Biotechnology sector has thinned, as evidenced by recent market offerings. As a result, the broker no longer views some of its previou...

Imugene stock rallies on positive Phase 2 trial into its lead drug candidate HER-Vaxx Hexima shares tank 88% after not so positive Phase 2 trial results to treat fungal nail infections Lumos Diagnostics completes $11.2 million cap raise a...

Antisense Therapeutics (ANP) announces positive results from its first animal study of its ATL1102 treatment against limb-girdle muscular dystrophy R2 (LGMDR2) As part of the study, ANP treated mice that had the rare disease with ATL1102 a...

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

ShareCafeKey Points To Remember When Investing in Biotech Companies In my role as Research Analyst for Corporate Connect, I have just released a report giving an in-depth assessment of the present state of the global biotech sector and, in...

Antisense Therapeutics (ASX:ANP) has announced that new data on ATL1102 in Duchenne muscular dystrophy will be presented in a poster presentation at a leading conference in the US.

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

Antisense Therapeutics (ANP) commences dosing in an animal model investigating the therapeutic potential of an antisense CD49d drug in a new inflammatory muscle disease The study is being conducted under the collaborative research agreemen...

ShareCafeThe Week that Was – January 17-21, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ShareCafeAntisense Therapeutics: The pathway to commercialisation Since ATL1102 returned impressive results in a phase II trial in non-ambulant Duchenne muscular dystrophy (naDMD) patients, Antisense Therapeutics (ASX: ANP) has been perfect...

Antisense Therapeutics (ANP) has raised just under $2.6 million from an entitlement offer which will be used for clinical research trials in Europe The company received applications from eligible shareholders for about 10.8 million shares...

The Antisense Therapeutics Limited (ASX: ANP) share price is moving higher today. This upwards movement comes amid the company’s annual general meeting (AGM). Usually, these events are not considered to be price-sensitive. However, the bio...